Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of fruquintinib + decitabine + tislelizumab in metastatic colorectal cancer
ChiCTR2300071824Phase 2Recruiting
- Sponsor
- Chongqing Traditional Chinese Medicine Hospital
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib, decitabine and tislelizumab in colorectal cancer (CRC), sponsored by Chongqing Traditional Chinese Medicine Hospital. Primary endpoint: overall response rate. Started Jun 2023; status: recruiting.
02
Drugs
fruquintinibdecitabinetislelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2300071824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071824.